13 results
10-K
2023 FY
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more
424B4
NMRA
Neumora Therapeutics Inc.
18 Sep 23
Prospectus supplement with pricing info
4:12pm
to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product
S-1/A
NMRA
Neumora Therapeutics Inc.
11 Sep 23
IPO registration (amended)
6:07am
are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one
S-1
NMRA
Neumora Therapeutics Inc.
25 Aug 23
IPO registration
5:03pm
limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval
DRS/A
b8feh3aikqx9jg 58l7q
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
oyjd7bsvic
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
ls7lc05q
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
x4b61tj mh7dz
2 Sep 22
Draft registration statement (amended)
12:00am
DRS/A
6h6yj2
10 Jun 22
Draft registration statement (amended)
12:00am
DRS/A
i4lqn
2 May 22
Draft registration statement (amended)
12:00am
DRS/A
8as542 s8mltan
23 Dec 21
Draft registration statement (amended)
12:00am
DRS
ynixu6sb
8 Nov 21
Draft registration statement
12:00am
- Prev
- 1
- Next